X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20418) 20418
Newspaper Article (6306) 6306
Book Review (4276) 4276
Publication (1387) 1387
Newsletter (666) 666
Conference Proceeding (313) 313
Magazine Article (281) 281
Trade Publication Article (274) 274
Book Chapter (178) 178
Web Resource (145) 145
Book / eBook (143) 143
Dissertation (70) 70
Report (40) 40
Transcript (25) 25
Government Document (9) 9
Reference (9) 9
Data Set (1) 1
Paper (1) 1
Presentation (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14816) 14816
insulin (14510) 14510
diabetes (13256) 13256
humans (12158) 12158
glucose (7603) 7603
female (7466) 7466
male (7256) 7256
disease (4780) 4780
insulin resistance (4605) 4605
insulin-resistance (4597) 4597
obesity (4451) 4451
risk factors (4432) 4432
adult (4364) 4364
middle aged (4359) 4359
endocrinology & metabolism (4352) 4352
research & development--r&d (4059) 4059
costs (4048) 4048
type 2 diabetes (3910) 3910
diabetes mellitus (3763) 3763
animals (3589) 3589
aged (2909) 2909
research (2843) 2843
analysis (2659) 2659
metabolic syndrome (2579) 2579
health aspects (2439) 2439
body mass index (2301) 2301
prevalence (2251) 2251
nutrition & dietetics (2174) 2174
studies (1991) 1991
adolescent (1924) 1924
diet (1851) 1851
mellitus (1759) 1759
metabolism (1750) 1750
hypoglycemic agents - therapeutic use (1737) 1737
care and treatment (1734) 1734
medicine (1678) 1678
risk (1655) 1655
diabetes mellitus, type 2 - drug therapy (1630) 1630
mortality (1578) 1578
diabetes therapy (1570) 1570
blood glucose - metabolism (1567) 1567
child (1513) 1513
insulin - therapeutic use (1456) 1456
physiological aspects (1449) 1449
patients (1415) 1415
cross-sectional studies (1391) 1391
medical research (1374) 1374
food science & technology (1359) 1359
children (1358) 1358
research article (1341) 1341
glycemic control (1328) 1328
medicine, general & internal (1324) 1324
epidemiology (1311) 1311
hypertension (1296) 1296
medicine & public health (1279) 1279
cardiovascular disease (1275) 1275
hyperglycemia (1263) 1263
hypoglycemia (1230) 1230
proteins (1226) 1226
population (1208) 1208
cardiovascular-disease (1205) 1205
socioeconomic factors (1205) 1205
insulin - blood (1200) 1200
internal medicine (1190) 1190
inflammation (1189) 1189
risk-factors (1185) 1185
mice (1182) 1182
rats (1169) 1169
young adult (1167) 1167
adults (1139) 1139
nutrition (1126) 1126
dextrose (1125) 1125
abridged index medicus (1120) 1120
multidisciplinary sciences (1103) 1103
body weight (1098) 1098
pregnancy (1091) 1091
public health (1090) 1090
health economics (1082) 1082
oxidative stress (1066) 1066
blood pressure (1059) 1059
diabetes mellitus, type 2 - epidemiology (1043) 1043
cholesterol (1037) 1037
pharmacology & pharmacy (1024) 1024
insulin - administration & dosage (1022) 1022
type 1 diabetes (1011) 1011
association (1002) 1002
public, environmental & occupational health (999) 999
article (983) 983
prevention (975) 975
hypoglycemic agents - administration & dosage (959) 959
exercise (953) 953
endocrinology (952) 952
health (950) 950
women (940) 940
cardiovascular diseases (930) 930
science (929) 929
metabolic disorders (915) 915
blood glucose - analysis (909) 909
type 2 diabetes mellitus (909) 909
clinical trials (906) 906
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (71) 71
Online Resources - Online (25) 25
Collection Dvlpm't (Acquisitions) - Vendor file (16) 16
Baycrest Hospital - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Robarts - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
UofT at Mississauga - Stacks (3) 3
Lakeridge Health Sciences - Oshawa (2) 2
Media Commons - Microtexts (2) 2
Scarborough Hospital - Birchmount (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
St. Michael's Hospital - Stacks (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Thomas Fisher Rare Book - Rare Book (2) 2
Baycrest Hospital - Resident/Client Library (1) 1
Engineering & Comp. Sci. - Material is damaged (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Massey College (Robertson Davies) - Rare Book (1) 1
Media Commons - Audio Visual (1) 1
Royal Ontario Museum - Periodical Stacks (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Online (1) 1
St Josephs Health Centre - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
University Archives - Archives (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Mississauga - Not Returned (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28132) 28132
Spanish (84) 84
German (77) 77
French (56) 56
Portuguese (35) 35
Swedish (10) 10
Chinese (9) 9
Dutch (8) 8
Polish (8) 8
Russian (8) 8
Danish (7) 7
Turkish (7) 7
Korean (6) 6
Czech (5) 5
Japanese (4) 4
Italian (3) 3
Finnish (2) 2
Hungarian (2) 2
Norwegian (2) 2
Serbian (2) 2
Slovenian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Persian (1) 1
Romanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1688 - 1697
Aims: To estimate the long-term cost-effectiveness of exenatide twice daily vs insulin glargine once daily as add-on therapy to oral antidiabetic agents (OADs)... 
pharmaco‐economics | antidiabetic drug | cost‐effectiveness | type 2 diabetes | insulin therapy | exenatide | cost-effectiveness | pharmaco-economics | METFORMIN | RISK-FACTORS | CARDIOVASCULAR OUTCOMES | RETROSPECTIVE COHORT | MELLITUS | MODEL | ADHERENCE | ENDOCRINOLOGY & METABOLISM | LIFETIME HEALTH OUTCOMES | WEIGHT-GAIN | UTILITY | Hypoglycemia - epidemiology | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diabetic Cardiomyopathies - economics | Models, Economic | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Diabetic Angiopathies - prevention & control | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Diabetic Angiopathies - economics | Direct Service Costs | Administration, Oral | Venoms - adverse effects | Hyperglycemia - economics | Drug Therapy, Combination - economics | Diabetic Angiopathies - therapy | Diabetic Cardiomyopathies - epidemiology | Venoms - therapeutic use | Quality of Life | Hyperglycemia - epidemiology | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Cardiovascular Diseases - therapy | Diabetes Mellitus, Type 2 - economics | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Peptides - economics | Venoms - administration & dosage | Diabetic Cardiomyopathies - prevention & control | Diabetic Cardiomyopathies - therapy | Hypoglycemia - economics | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - economics | Insulin Glargine - adverse effects | Drug Administration Schedule | Venoms - economics | Insulin Glargine - economics | Insulin Glargine - therapeutic use | China - epidemiology | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Cost-Benefit Analysis | Incretins - adverse effects | Diabetic Angiopathies - epidemiology | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | Peptides - adverse effects | Peptides - therapeutic use | Incretins - economics | Type 2 diabetes | Insulin | Analysis | Diabetes therapy | Literature reviews | Databases | Diabetes mellitus | Clinical trials | Diabetes | Cost analysis | Hypoglycemia | Patients | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
The study is unique in reporting resource use associated with severe hypoglycaemia from a randomized controlled trial setting, because resource use has... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | OPEN-LABEL | TO-TARGET TRIAL | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 5, pp. 1338 - 1345
Journal Article
JAMA, ISSN 0098-7484, 05/2002, Volume 287, Issue 19, pp. 2542 - 2551
CONTEXT Several treatment interventions can reduce complications of type 2 diabetes, but their relative cost-effectiveness is not known. OBJECTIVE To estimate... 
UNITED-STATES | MORTALITY | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MYOCARDIAL-INFARCTION | DIRECT MEDICAL COSTS | SECULAR TRENDS | MICROVASCULAR COMPLICATIONS | CORONARY HEART-DISEASE | BLOOD-GLUCOSE CONTROL | Insulin - economics | Markov Chains | Hypoglycemic Agents - economics | United States | Cholesterol - blood | Humans | Middle Aged | Diabetes Mellitus, Type 2 - economics | Pravastatin - economics | Angiotensin-Converting Enzyme Inhibitors - economics | Sulfonylurea Compounds - economics | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adrenergic beta-Antagonists - economics | Aged, 80 and over | Adult | Diabetic Angiopathies - prevention & control | Diabetic Nephropathies - prevention & control | Pravastatin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Antihypertensive Agents - economics | Diabetic Neuropathies - economics | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Diabetic Angiopathies - economics | Diabetic Neuropathies - prevention & control | Sulfonylurea Compounds - therapeutic use | Anticholesteremic Agents - economics | Diabetes Mellitus, Type 2 - prevention & control | Antihypertensive Agents - therapeutic use | Disease Progression | Diabetic Nephropathies - economics | Anticholesteremic Agents - therapeutic use | Diabetes Mellitus, Type 2 - physiopathology | Cost-Benefit Analysis | Aged | Insulin - therapeutic use | Hypertension | Care and treatment | Hypercholesterolemia | Analysis | Diabetes | Drug therapy | Medical care, Cost of | Cost estimates | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2016, Volume 11, Issue 9, pp. e0162951 - e0162951
The costs of drug-induced hypoglycemia are a critical but often neglected component of value-based arguments to reduce tight glycemic control in older adults... 
Insulin - economics | Outcome Assessment (Health Care) - methods | United States - epidemiology | Hypoglycemia - epidemiology | Metformin - therapeutic use | Hypoglycemic Agents - economics | Humans | Diabetes Mellitus, Type 2 - economics | Models, Economic | Metformin - adverse effects | Sulfonylurea Compounds - economics | Incidence | Metformin - economics | Thiazolidinediones - therapeutic use | Canada - epidemiology | Aged, 80 and over | Hypoglycemia - economics | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Sulfonylurea Compounds - therapeutic use | Thiazolidinediones - economics | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Outcome Assessment (Health Care) - economics | Cost-Benefit Analysis | Aged | Decision Trees | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Monte Carlo Method | Insulin - therapeutic use | Type 2 diabetes | Prevention | Glucagon | Economic aspects | Glucose | Comparative analysis | Medical economics | Dextrose | Diabetes therapy | Health care | Elderly people | Economic analysis | Costs | Systematic review | Emergency medical care | Body mass index | Older people | Population | Diabetes mellitus (non-insulin dependent) | Public health | Diabetes mellitus | Hypoglycemia | Decision analysis | Insulin | Patients | Cost control | Quality of life | Government programs | Pharmacy | Adults | Diabetes | Metformin | Cost analysis | Thiazolidinediones | Age groups | Index Medicus
Journal Article
European Heart Journal, ISSN 0195-668X, 07/2013, Volume 34, Issue 28, pp. 2149 - 2157
STATEMENT | NERVOUS-SYSTEM | GENERATED SYMPATHETIC ACTIVITY | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | ABLATION | MECHANISMS | RESISTANT ARTERIAL-HYPERTENSION | BLOOD-PRESSURE | ATRIAL-FIBRILLATION | HEMODYNAMICS | Postoperative Complications - economics | Postoperative Complications - etiology | Humans | Hypertension - drug therapy | Catheter Ablation - economics | Surgicenters - statistics & numerical data | Patient Selection | Electrodes | Multicenter Studies as Topic | Insulin Resistance - physiology | Sympathectomy - methods | Surgicenters - economics | Hypertension - economics | Drug Resistance | Antihypertensive Agents - economics | Arrhythmias, Cardiac - prevention & control | Sympathectomy - instrumentation | Treatment Outcome | Hypertension - surgery | Cardio-Renal Syndrome - prevention & control | Antihypertensive Agents - therapeutic use | Randomized Controlled Trials as Topic | Renal Artery - innervation | Catheter Ablation - methods | Diabetes Mellitus - prevention & control | Cost-Benefit Analysis | Catheter Ablation - instrumentation | Renal Artery - surgery | Sympathectomy - economics | Index Medicus | methods | Catheter Ablation | Renal Artery | Kardiologi | Cardio-Renal Syndrome | Antihypertensive Agents | instrumentation | innervation | Postoperative Complications | Hypertension | drug therapy | Sympathectomy | Cardiac | Insulin Resistance | physiology | prevention & control | Diabetes Mellitus | etiology | Surgicenters | Cardiac and Cardiovascular Systems | economics | statistics & numerical data | therapeutic use | Arrhythmias | surgery
Journal Article
Diabetic Medicine, ISSN 0742-3071, 07/2015, Volume 32, Issue 7, pp. 890 - 898
Dapagliflozin is a selective sodium–glucose co–transporter–2 (SGLT‐2) inhibitor licensed in the European Union (EU) for use in people with Type 2 diabetes... 
HEALTH-RELATED UTILITY | INSULIN | THERAPY | MODELS | SAXAGLIPTIN | ENDOCRINOLOGY & METABOLISM | HYPOGLYCEMIA | WEIGHT-GAIN | COMPLICATIONS | INADEQUATE GLYCEMIC CONTROL | STRATEGIES | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Humans | Middle Aged | Male | Diabetes Complications - therapy | Weight Loss - drug effects | Metformin - adverse effects | Metformin - economics | Sodium-Glucose Transport Proteins - metabolism | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Hyperglycemia - prevention & control | Hyperglycemia - economics | Diabetes Complications - economics | Drug Therapy, Combination - economics | Overweight - prevention & control | Overweight - therapy | Glucosides - economics | Hypoglycemic Agents - adverse effects | Cohort Studies | Metformin - therapeutic use | Diabetes Mellitus, Type 2 - economics | Risk | Diabetes Mellitus, Type 2 - metabolism | Sulfonylurea Compounds - economics | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Benzhydryl Compounds - adverse effects | Overweight - epidemiology | Diabetes Complications - epidemiology | Female | Glucosides - therapeutic use | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Sulfonylurea Compounds - therapeutic use | Benzhydryl Compounds - economics | Sulfonylurea Compounds - adverse effects | Health Care Costs | Cost-Benefit Analysis | Sodium-Glucose Transport Proteins - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | United Kingdom - epidemiology | Type 2 diabetes | Analysis | Development and progression | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1921 - 1927
Aims The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant... 
cost‐effectiveness | GLP‐1 analogue | type 2 diabetes | incretin therapy | liraglutide, sitagliptin | cost-effectiveness | GLP-1 analogue | liraglutide | VALIDATION | UTILITY VALUES | MELLITUS | MODEL | sitagliptin | DISEASE | ENDOCRINOLOGY & METABOLISM | MULTIFACTORIAL INTERVENTION | COMPLICATIONS | OUTCOMES | Anti-Obesity Agents - economics | Hypoglycemia - therapy | Overweight - complications | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Overweight - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Anti-Obesity Agents - adverse effects | Diabetes Mellitus, Type 2 - economics | Diabetes Complications - therapy | Diabetes Mellitus, Type 2 - metabolism | Models, Economic | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Liraglutide - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Hypoglycemia - prevention & control | Overweight - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Diabetes Complications - epidemiology | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hyperglycemia - economics | Risk Factors | Sitagliptin Phosphate - economics | Diabetes Complications - economics | Health Care Costs | Liraglutide - adverse effects | Cost-Benefit Analysis | Liraglutide - therapeutic use | Quality of Life | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hyperglycemia - therapy | Hypoglycemic Agents - adverse effects | United Kingdom - epidemiology | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Cost benefit analysis | Health aspects | Analysis | Body mass index | Costs | Statistical analysis | Life span | Diabetes mellitus | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Patients | Clinical outcomes | Index Medicus
Journal Article